Bristol-Myers Squibb Co.'s Proposed Senior Unsecured Notes Rated 'A+'

NEW YORK (S&P Global Ratings) Nov. 9, 2020--S&P Global Ratings today assigned its 'A+' issue-level ratings to New York City-based pharmaceutical company Bristol-Myers Squibb Co.'s proposed senior unsecured notes. The company plans to use the proceeds from these notes to partially fund its $13.1 billion acquisition of MyoKardia Inc., which it announced on Oct. 5, 2020. Our ratings on Bristol-Myers reflects its position as one of the largest branded pharmaceutical companies in the world with pro forma revenue of about $40 billion (including revenue from Celgene Corp.). It holds a leading position in oncology, which is a growth area, alongside Roche. The company also has eight blockbuster drugs, several new drug launches, and a solid pipeline, which it bolstered through

...- General Criteria: Group Rating Methodology, July 1, 2019 - Criteria | Corporates | General: Corporate Methodology: Ratios And Adjustments, April 1, 2019 - Criteria | Corporates | General: Reflecting Subordination Risk In Corporate Issue Ratings, March 28, 2018 - General Criteria: Methodology For Linking Long-Term And Short-Term Ratings, April 7, 2017 - Criteria | Corporates | General: Methodology And Assumptions: Liquidity Descriptors For Global Corporate Issuers, Dec. 16, 2014 - Criteria | Corporates | Industrials: Key Credit Factors For The Pharmaceutical Industry, April 8,...

Ratings Action